Overview Financials News + Filings Key Docs Charts Holdings Ownership
|
|
WuXi PharmaTech (Cayman) Inc. (WX)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 62.7% | 63.4% | 63.3% | 61.6% | 61.8% | 59.9% | 62.0% |
| Gross profit | 37.3% | 36.6% | 36.7% | 38.4% | 38.2% | 40.1% | 38.0% |
| Sales and marketing | 0.1% | 0.1% | 3.1% | 2.5% | 0.0% | 2.8% | 2.9% |
| Research and development | 3.1% | 1.9% | 1.6% | 1.3% | 0.1% | | |
| General and administrative | 3.4% | 2.7% | 2.9% | 2.8% | 3.1% | 5.8% | 19.5% |
| EBITDA | 22.3% | 25.9% | 26.9% | 28.9% | 30.1% | 28.2% | 27.9% |
| Depreciation | 6.9% | 7.7% | 8.3% | 8.3% | 8.7% | 8.9% | 12.2% |
| EBIT | 15.4% | 18.2% | 18.6% | 20.6% | 21.4% | 19.3% | 15.6% |
| Pre-tax income | 16.6% | 19.8% | 17.2% | 19.9% | 27.2% | 19.6% | -7.5% |
| Income taxes | -3.6% | -4.1% | -0.2% | -4.1% | 0.0% | -0.1% | -1.6% |
| Net income | 16.6% | 19.8% | 17.3% | 19.9% | 27.2% | 19.6% | -25.3% |
|